INTRODUCTION {#s1}
============

Screening for colorectal cancer (CRC) is employed in an increasing number of countries due to its proven efficacy in reducing CRC incidence and mortality \[[@R1]--[@R9]\], and an increasing share of CRC cases is diagnosed by screening rather than by symptoms. It is to be expected that patients with screen-detected CRC have better prognosis than patients with symptom-detected CRC due to earlier diagnosis and potentially other favorable tumor or host characteristics. However, it is unclear to what extent survival advantages persist within stages at diagnosis. Direct evidence on overall and stage-specific survival expectations of patients with screen-detected CRC is surprisingly sparse. Such evidence would though be of major clinical and public health interest for several reasons: First, it may alleviate the fear of having a diagnosis of CRC at screening which may be a major obstacle for people to undergo CRC screening. Second, it may alleviate fears of patients after a CRC diagnosis at screening. Third, it may enhance the basis for clinical decision making.

In this manuscript, we provide a detailed assessment of prognosis of CRC patients according to type of diagnosis (detection by symptoms, screening colonoscopy, fecal occult blood test \[FOBT\], or otherwise) in a large multi-center cohort of CRC patients from Germany for whom detailed information on the diagnostic process was obtained.

MATERIALS AND METHODS {#s2}
=====================

Study design and study population {#s2_1}
---------------------------------

In Germany, screening colonoscopy is offered to the average risk population from age 55 on. Screening by (guaiac based) FOBT is offered annually at ages 50 to 54. From age 55 on, FOBT every two years is offered as an alternative to screening colonoscopy. To assess the impact of screening, the DACHS (Darmkrebs: Chancen der Verhütung durch Screening) study was initiated in the Rhine-Neckar area of Germany in 2003. DACHS is a population-based case-control study with additional comprehensive follow-up of cases. Details of the study design and data collection have been reported previously \[[@R10]--[@R12]\]. Briefly, patients with a first diagnosis of CRC (ICD 10 codes C18-C20) aged 30 years or older are recruited in all of the 22 hospitals providing CRC surgery in the study region (approximately 2 million inhabitants). Matched controls are randomly selected from population registries. The study was approved by the ethics committees of the Medical Faculty of the University of Heidelberg and of the Medical Chambers of Baden-Württemberg and Rhineland-Palatinate. Written informed consent is obtained from each participant. Participants for the current analysis were selected from 3,146 cases recruited from 2003 to 2010 and followed with respect to survival to 2013.

Data collection {#s2_2}
---------------

Personal interviews with cases were conducted by trained interviewers using a standardized questionnaire. Interviews were conducted during hospital stay, typically a few days after surgery, wherever possible, or after hospital discharge at the patients' homes otherwise. In addition, medical data were extracted from hospital charts. The interviews lasted for about one hour and addressed potential CRC risk factors, preventive factors and prognostic factors in great detail. In addition, detailed information was collected on history of CRC screening and the basis for the current CRC diagnosis. In particular, patients were asked if the diagnosis was made by work-up of symptoms, by a screening examination or incidentally (e.g. in the context of medical examination for other reasons). If the cancer was detected by screening, the type and sequence of screening examinations was ascertained.

Data extracted from medical charts include tumor stage and location in particular. Three years after diagnosis, standardized information on CRC therapy was obtained from the physicians of the patients. Three and 5 years after diagnosis, vital status was ascertained through systematic follow-up by record linkage with population registries. For deceased patients, cause of death was extracted from death certificates which were obtained from local public health authorities.

Statistical analysis {#s2_3}
--------------------

For statistical analysis, the following consecutive exclusions were made (numbers and reasons given in parentheses): \<50 or \>=80 years of age (n=664; screening not commonly offered or recommended for the average risk population at these ages), history of inflammatory bowel disease (n=19; frequent surveillance colonoscopies due to increased risk of CRC), missing information on the mode of CRC detection (n=2), and missing follow-up data (n=11). After these exclusions, there remained 2,450 cases for the analysis.

We first described cases according to age, sex, education, stage (using the Union Internationale Contre le Cancer \[UICC\] classification), site (proximal colon, cecum to transverse colon; distal colon, left flexure to sigmoid colon; rectum) and mode of detection (symptoms; screening colonoscopy; FOBT; other, such as incidental detection in the course of other diagnostic measures) of the cancer. Differences in age, sex, education, stage, and site distributions by mode of detection were assessed by Chi square tests.

Next, we assessed overall and CRC specific survival according to mode of detection. Survival time was calculated from the day of diagnosis to the day of death (deceased patients) or censored at the date of the last follow-up. In cause specific survival analyses survival time was censored at the day of death from other reasons.

Survival was compared by mode of detection using direct adjusted survival curves (adjusted for age and sex). In addition, Cox proportional hazards models were run to evaluate the association of mode of detection with survival outcomes using various levels of adjustment: Model 1 adjusted for sociodemographic variables only (sex, age, education). Model 2 additionally adjusted for key tumor characteristics, i.e., stage and location. In order to assess potential variation of results according to specific treatments, Cox proportional hazards models were repeated after excluding 304 patients who had received neoadjuvant therapy in sensitivity analyses. Furthermore, we carried out specific analyses on CRC specific survival for subgroups defined by tumor stage and location, by conduct of chemotherapy among stage II and stage III patients, and by sex and age. In all Cox models, the proportional hazards assumption was checked by testing for interaction of the covariates with follow-up time and interaction terms were added as needed.

All statistical analyses were carried out using SAS statistical software, version 9.3 (SAS Institute Inc., Cary, North Carolina). An alpha level of 0.05 was employed for statistical tests.

RESULTS {#s3}
=======

Table [1](#T1){ref-type="table"} shows characteristics of the study population which included 1520 (62%) male and 930 (38%) female patients. The majority of patients were between 60 and 79 years old (82%; median: 68 years), were diagnosed at stage II or III (62%), and had their cancer detected by symptoms (68%). Screening colonoscopy, FOBT and other reasons led to the diagnosis in approximately 10% each.

###### Characteristics of the study population

  Characteristic                                       Men    Women   Total                
  ---------------------------------------------------- ------ ------- ------- ----- ------ -----
  *Age*                                                                                    
   50-59 years                                         273    18%     175     19%   448    18%
   60-69 years                                         636    42%     363     39%   999    41%
   70-79 years                                         611    40%     392     42%   1003   41%
  *Education[^a^](#tfn_001){ref-type="table-fn"}*                                          
   ≤9 years                                            1057   70%     651     70%   1708   70%
   10-11 years                                         204    13%     178     19%   382    16%
   12+ years                                           259    17%     97      11%   356    14%
  *Cancer stage[^b^](#tfn_002){ref-type="table-fn"}*                                       
   I                                                   365    24%     210     23%   575    23%
   II                                                  459    30%     289     31%   748    31%
   III                                                 460    31%     304     33%   764    31%
   IV                                                  231    15%     125     13%   356    15%
  *Cancer site*[^c^](#tfn_003){ref-type="table-fn"}                                        
   Proximal colon                                      399    26%     332     36%   731    30%
   Distal colon                                        419    28%     268     29%   687    28%
   Rectum                                              699    46%     327     35%   1026   42%
  *Mode of detection*                                                                      
   Symptoms                                            997    66%     673     73%   1670   68%
   Screening colonoscopy                               183    12%     96      10%   279    11%
   FOBT                                                168    11%     75      8%    243    10%
   Other                                               172    11%     86      9%    258    11%

FOBT, fecal occult blood test

Information missing for 4 patients.

Information missing for 7 patients.

Information missing for 6 patients.

Patients whose cancer was detected by screening colonoscopy more often had higher education than patients with symptom-detected cancer (Table [2](#T2){ref-type="table"}). Furthermore, their cancer was detected much more often in stage I (50% versus 17%), and located in the colon (69% versus 53%). FOBT detected cancers also had a more favourable stage distribution than symptom-detected cancers, with only 4% of cancers detected in stage IV, compared to 17% for symptom-detected cancers and 5% for screening colonoscopy-detected cancers. However, the proportion of stage I cancers was lower than among screening colonoscopy-detected cancers.

###### Association of mode of detection with patient and tumor characteristics

  Characteristic   Mode of detection                                                                 
  ---------------- ------------------- ----- ----- ----- --------- ----- ----- --------- ----- ----- ---------
  *Age*                                                                                              
   50-59           322                 19%   40    14%   0.037     47    19%   0.43      39    15%   0.066
   60-69           679                 41%   134   48%             89    37%             97    38%   
   70-79           669                 40%   105   38%             107   44%             122   47%   
  *Sex*                                                                                              
   Men             997                 60%   183   66%   0.062     168   69%   0.005     172   67%   0.033
   Women           673                 40%   96    34%             75    31%             86    33%   
  *Education*                                                                                        
   ≤9 years        1189                71%   175   63%   0.003     163   67%   0.262     181   67%   0.773
   10-11 years     258                 15%   47    17%             39    16%             38    16%   
   12+ years       220                 13%   57    20%             41    17%             38    17%   
  *Cancer stage*                                                                                     
   I               291                 17%   139   50%   \<0.001   83    34%   \<0.001   62    24%   0.048
   II              545                 33%   47    17%             82    34%             74    29%   
   III             547                 33%   76    27%             67    28%             74    29%   
   IV              283                 17%   15    5%              10    4%              48    18%   
  *Cancer* site                                                                                      
   Prox. colon     428                 26%   97    35%   \<0.001   88    36%   \<0.001   118   46%   \<0.001
   Distal colon    449                 27%   96    34%             72    30%             70    28%   
   Rectum          790                 47%   86    31%             83    34%             67    26%   

FOBT, fecal occult blood test

p-value for difference from participants whose cancer was detected by symptoms

During a median follow-up time of 4.8 years (interquartile range: 3.0 to 5.1 years), 590 (24%) patients died, of whom 461 (78%) died from CRC. Direct adjusted survival curves are shown in Figure [1](#F1){ref-type="fig"}. Patients whose cancer was detected by screening colonoscopy or FOBT had substantially higher overall survival and CRC specific survival 5 years after diagnosis (\>85% and \>90%, respectively) than patients whose cancer was detected by symptoms or otherwise (\<70% and \<75%, respectively). After adjustment for age, sex and education, patients whose cancer was detected by screening colonoscopy had a 65% lower total mortality than patients with symptom-detected cancers (hazard ratio, HR, 0.35, 95% confidence interval, 95% CI, 0.24-0.50) (Table [3](#T3){ref-type="table"}). A 50% mortality reduction persisted even after additional control for stage and location of the cancer (HR 0.50, 95% CI 0.34-0.73). Similarly decreased total mortality was seen for patients whose cancer was detected by FOBT. Even stronger reductions were seen for CRC mortality, with fully adjusted hazard ratios of 0.36 (95% CI 0.21-0.60) and 0.47 (95% CI 0.29-0.77) for patients with screening colonoscopy and FOBT-detected cancers, respectively. By contrast, no difference was seen in mortality from other causes between patients with screen-detected and symptom-detected cancer. Sensitivity analyses excluding 304 patients who had received neoadjuvant therapy did not materially change any of the observed associations (fully adjusted HRs (95% CIs) for CRC mortality: 0.38 (95% CI 0.23-0.64) and 0.48 (95% CI 0.29-0.79) for colonoscopy- and FOBT detected cancers, respectively). The same applies to sensitivity analyses specifically adjusting for T- and N-status in addition to UICC stage (fully adjusted HRs (95% CIs) for CRC mortality: 0.37 (95% CI 0.21-0.64) and 0.52 (95% CI 0.31-0.85) for colonoscopy- and FOBT detected cancers, respectively).

![Direct adjusted survival curves according to mode of cancer detection for A\
overall and **B.** CRC-specific survival, **C.** non-CRC-specific survival and **D, E, F.** according to mode of detection and stage at diagnosis (all survival curves were adjusted for age and sex).](oncotarget-07-44695-g001){#F1}

###### Hazard ratios for total, CRC specific and other mortality according to mode of detection

  Outcome, mode of detection   Mortality   Hazard Ratios                                      
  ---------------------------- ----------- --------------- ------ ------ ------------- ------ -------------
  *Total mortality*                                                                           
   Symptoms                    461         5815            79.3   1.00   Ref.          1.00   Ref.
   Screening colonoscopy       30          1073            28.0   0.35   (0.24-0.50)   0.50   (0.34-0.73)
   FOBT                        29          971             29.9   0.36   (0.25-0.53)   0.54   (0.37-0.80)
   Other                       70          899             77.9   0.94   (0.73-1.21)   0.86   (0.66-1.11)
  *CRC mortality*                                                                             
   Symptoms                    373         5815            64.1   1.00   Ref.          1.00   Ref.
   Screening colonoscopy       15          1073            14.0   0.21   (0.13-0.36)   0.36   (0.21-0.60)
   FOBT                        17          971             17.5   0.27   (0.17-0.44)   0.47   (0.29-0.77)
   Other                       56          899             62.3   0.93   (0.70-1.23)   0.85   (0.63-1.13)
  *Non CRC mortality*                                                                         
   Symptoms                    88          5815            15.1   1.00   Ref.          1.00   Ref.
   Screening colonoscopy       15          1073            14.0   0.92   (0.53-1.59)   0.94   (0.53-1.67)
   FOBT                        12          971             12.4   0.73   (0.40-1.33)   0.74   (0.40-1.37)
   Other                       14          899             15.6   0.99   (0.56-1.74)   0.96   (0.54-1.72)

FOBT, fecal occult blood test; HR, hazard ratio, 95% CI, 95% confidence interval

Adjusted for age, sex, and education, and for a time-dependent effect of age and sex.

Additionally adjusted for stage and location of the cancer, and for time-dependent effects of stage and location.

Given very similar results for survival of patients with screening colonoscopy and FOBT-detected cancers both groups were combined in further, subgroup specific analyses. Strongly reduced CRC specific mortality for patients with screening colonoscopy or FOBT-detected compared to symptom-detected cancers was consistently seen even after full adjustment for all subgroups defined by tumor stage or location (Table [4](#T4){ref-type="table"}, Figure [1](#F1){ref-type="fig"}, Panels D, E, F), sex or age (Table [5](#T5){ref-type="table"}). With a 74% lower CRC specific mortality for screen-detected compared to symptoms-detected cancers, the association was particularly strong among stage II-III patients who received chemotherapy. Additional subgroup analyses among stage III patients by number of affected lymph nodes (N1: 1-3 lymph nodes, N2: 4+ lymph nodes) confirmed substantially lower CRC mortality for patients with screen-detected CRC than for patients with symptom-detected CRC within both subgroups (N1: HR 0.34, 95% CI 0.14-0.81; N2: HR 0.39, 95% CI 0.40-1.10). Among patients with screen-detected stage III CRC, 5-year CRC specific survival was as high (slightly above 90%) as among patients with symptom-detected stage I or II CRC (Figure [1](#F1){ref-type="fig"}, Panels D and E). The small number of patients with screen-detected stage IV CRC had approximately two-fold higher 5-year CRC-specific survival (40% versus 20%) and 2-fold longer median CRC-specific survival (4 versus 2 years) compared to patients with symptom-detected stage IV CRC (Figure [1](#F1){ref-type="fig"}, Panel F).

###### Hazard ratios for CRC-specific mortality according to mode of detection and stage at diagnosis and location of tumor

  Patient / tumor characteristics, mode of detection                                      Deaths   Person-years   Rate per 1,000 person-yrs   Fully adjusted hazard ratio [^a^](#tfn_007){ref-type="table-fn"}   
  --------------------------------------------------------------------------------------- -------- -------------- --------------------------- ------------------------------------------------------------------ -------------
  *Stage I + II*                                                                                                                                                                                                 
   Symptoms                                                                               60       3225           18.6                        1.00                                                               Ref.
   Any screening                                                                          8        1410           5.7                         0.29                                                               (0.14-0.61)
   Other                                                                                  5        528            9.5                         0.46                                                               (0.18-1.17)
  *Stage III*                                                                                                                                                                                                    
   Symptoms                                                                               102      1983           51.4                        1.00                                                               Ref.
   Any screening                                                                          10       547            18.3                        0.33                                                               (0.17-0.64)
   Other                                                                                  14       266            52.6                        0.86                                                               (0.47-1.57)
  *Stage IV*                                                                                                                                                                                                     
   Symptoms                                                                               209      597            350.1                       1.00                                                               Ref.
   Any screening                                                                          14       72             194.4                       0.52                                                               (0.30-0.90)
   Other                                                                                  37       105            352.4                       0.92                                                               (0.64-1.31)
  *Stage II-III patients who received chemotherapy[^b^](#tfn_008){ref-type="table-fn"}*                                                                                                                          
   Symptoms                                                                               98       2452           40.0                        1.00                                                               Ref.
   Any screening                                                                          7        583            12.0                        0.26                                                               (0.12-0.56)
   Other                                                                                  11       270            40.7                        0.69                                                               (0.35-1.36)
  *Stage II-III patients who did not receive chemotherapy*                                                                                                                                                       
   Symptoms                                                                               84       2443           34.4                        1.00                                                               Ref.
   Any screening                                                                          10       621            16.1                        0.45                                                               (0.23-0.87)
   Other                                                                                  7        312            22.4                        0.67                                                               (0.30-1.48)
  *Proximal colon*                                                                                                                                                                                               
   Symptoms                                                                               112      1380           81.2                        1.00                                                               Ref.
   Any screening                                                                          11       721            15.3                        0.32                                                               (0.17-0.60)
   Other                                                                                  22       431            51.0                        0.65                                                               (0.40-1.04)
  *Distal colon*                                                                                                                                                                                                 
   Symptoms                                                                               91       1627           55.9                        1.00                                                               Ref.
   Any screening                                                                          10       670            14.9                        0.47                                                               (0.24-0.93)
   Other                                                                                  20       225            88.9                        1.40                                                               (0.85-2.31)
  *Rectum*                                                                                                                                                                                                       
   Symptoms                                                                               168      2799           60.0                        1.00                                                               Ref.
   Any screening                                                                          11       653            16.8                        0.47                                                               (0.25-0.86)
   Other                                                                                  14       230            60.9                        0.70                                                               (0.40-1.22)

FOBT, fecal occult blood test; HR, hazard ratio; 95% CI, 95% confidence interval

Adjusted for age, sex, education, stage and location of the cancer, and for time-dependent effects of age, sex, stage and location.

Colon cancer patients who received chemotherapy after surgery for treatment of primary cancer; rectum cancer patients who received neoadjuvant therapy before surgery and/or chemotherapy after surgery for treatment of primary cancer.

###### Hazard ratios for CRC-specific mortality according to mode of detection and by age and sex

  Patient characteristics, mode of detection             Deaths   Person-years   Rate per 1,000 person-yrs   Fully adjusted hazard ratio [^a^](#tfn_009){ref-type="table-fn"}   
  ------------------------------------------------------ -------- -------------- --------------------------- ------------------------------------------------------------------ -------------
  *Men*                                                                                                                                                                         
   Symptoms                                              226      3420           66.1                        1.00                                                               Ref.
   Any screening                                         21       1371           15.3                        0.38                                                               (0.24-0.59)
   Other                                                 34       592            57.4                        0.75                                                               (0.52-1.08)
  *Women*                                                                                                                                                                       
   Symptoms                                              147      2395           61.4                        1.00                                                               Ref.
   Any screening                                         11       672            16.4                        0.45                                                               (0.24-0.83)
   Other                                                 22       307            71.7                        1.05                                                               (0.66-1.67)
  *Age ≤68 years*[^b^](#tfn_010){ref-type="table-fn"}                                                                                                                           
   Symptoms                                              212      3574           59.3                        1.00                                                               Ref.
   Any screening                                         15       1231           12.2                        0.38                                                               (0.22-0.65)
   Other                                                 24       499            48.1                        0.72                                                               (0.46-1.12)
  *Age \>68 years*[^b^](#tfn_010){ref-type="table-fn"}                                                                                                                          
   Symptoms                                              161      2241           71.8                        1.00                                                               Ref.
   Any screening                                         17       812            20.9                        0.43                                                               (0.26-0.72)
   Other                                                 32       400            80.0                        0.92                                                               (0.63-1.35)

FOBT, faecal occult blood test; HR, hazard ratio. 95% CI, 95% confidence interval

Adjusted for age, sex, education, stage and location of the cancer, and for time-dependent effects of age, sex, stage and location.

Age categorized at the median value

DISCUSSION {#s4}
==========

In this large cohort of patients with CRC recruited in the context of a population-based case-control study in Southern Germany, patients whose cancer was detected by screening colonoscopy or FOBT had strongly enhanced overall survival and even more strongly enhanced CRC specific survival compared to patients with symptom-detected cancer. Even though survival differences were partly explained by the more favourable stage distribution of patients with screening detected cancers, the largest share of the survival advantages persisted even after control for CRC stage, and large survival advantages were seen within each stage. Patients with screen-detected stage III CRC had as good CRC specific survival as patients with symptom-detected stage I or II CRC.

Our findings of more favourable stage distribution among screen-detected cancers than among symptom-detected cancers are consistent with previous reports from various countries including Germany \[e.g. [@R13]--[@R17]\]. Higher survival rates of patients with screen-detected CRC than of patients with symptom-detected CRC have also been repeatedly reported \[[@R16]--[@R25]\], but few studies have addressed survival by stage, and the survival advantage has primarily been attributed to more favorable stage distribution. However, in agreement with our findings, Mapp et al found a significant survival advantage in patients with screen-detected cancers in the Nottingham FOBT trial which persisted after control for tumor stage \[[@R19]\]. In two studies (n=633 and 514, respectively) conducted in the context of the FOBT based British Bowel Cancer Screening Programme, survival advantages for screen-detected cancers over symptom-detected cancers were likewise observed even in stage-specific and stage-adjusted analyses \[[@R22], [@R24]\]. Similar results were recently reported for screening colonoscopy detected colon cancer in a single center study (n=1,071) from the US \[[@R25]\]. In our multi-center study from Germany (n=2,450), we observed similarly strong survival advantages for patients with either FOBT or screening colonoscopy-detected CRC which were only reduced to a small extent and remained highly statistically significant after control for stage in multivariable analysis.

Higher survival of screening detected cases compared to symptom detected cases does not by itself prove any beneficial effects of screening. On the contrary, any screening leading to earlier diagnosis of cancer would be expected to go along with longer survival after diagnosis even if total mortality in the screened and unscreened population remained the same. In such a situation, the apparently longer survival after diagnosis might merely reflect lead time, i.e. advancement of the diagnosis by screening, unless the earlier diagnosis also enhances chances of cure. However, for CRC, chances of cure are strongly stage dependent, and the strong shift of the stage distribution towards earlier stages by colonoscopy or FOBT screening is expected to go along with substantially enhanced chances of cure.

Nevertheless, earlier diagnosis was not the only reason for the substantially enhanced survival of patients with screen-detected cancers because a strong survival advantage of this group persisted even after control for cancer stage and was observed for every stage in stage-specific analyses. Several mechanisms might explain this finding. First, confounding by stage might not be fully accounted for by the relatively crude classification of stage which is an extremely strong predictor of prognosis among CRC patients. However, results remained essentially unchanged in sensitivity analyses specifically adjusting for T- and N-status in addition to UICC stage, and very similar results were obtained after further stratification of stage III cancers according to number of affected lymph nodes. Relevant residual confounding by differences in tumor spread therefore appears unlikely. Second, more slowly growing cancers with more favourable prognosis might have a higher chance to be detected by screening and might be overrepresented in screen-detected cancers compared to symptom-detected cancers, a phenomenon known as "length time bias". Third, patients adherent to screening recommendations whose cancer was detected by screening might also be more adherent to therapy and might also otherwise behave more health conscious after diagnosis than patients with symptom-detected cancers. However, given that our findings persisted after control for education and given the similarity of non-CRC mortality among screen-detected and symptom-detected cancers, a major role of such "healthy screenee bias" seems unlikely.

Regardless of its origin, our findings of very favourable prognosis of screen-detected cancer cases might have important clinical and public health implications. First, the fear of a fatal diagnosis might prevent many people from using screening offers. Data showing that their prognosis is very good even in the unlikely case that a cancer is found at screening might help to alleviate such fears and enhance adherence to screening recommendations.

Second, direct evidence of relatively favorable prognosis may likewise alleviate fears of patients after a screening initiated diagnosis. Cancer patients are meanwhile often well informed on overall and stage specific cancer survival rates from internet or other information sources. Such survival rates typically do not differentiate between screen-detected and other cancers and may unduly discourage patients with screen-detected cancers. Knowledge of the true prognosis of patients with screen-detected cancers is equally important for the treating physicians and patient-physician interactions, as perspectives of survival and treatment success may impact on treatment decisions. There is ongoing active search for prognostic markers that may support judgment of prognosis as a basis for individual (personalized) treatment decisions. Our results suggest that mode of detection is an exceptionally informative marker in this context which is typically readily available or can be obtained at virtually no extra efforts and costs.

Our study has a number of strengths and limitations. To our knowledge, this is the first study simultaneously assessing and comparing survival outcomes of patients with screening colonoscopy detected CRC, FOBT-detected CRC and symptom-detected CRC, with and without stratification by and adjustment for cancer stage as well as a number of other relevant prognostic factors. Patients were recruited after diagnosis, in most cases during hospital stay or early after discharge. As a result, patients with very early deaths or too sick to participate are likely to be underrepresented. This might have increased observed absolute survival proportions to some extent but should not have affected hazard ratios comparing survival between patient groups. Causes of death were extracted from death certificates which are known to be prone to imprecision and coding errors. However, the validity of recorded cause of death has been consistently found to be much higher for cancers than for other causes of death \[[@R26]\]. Despite the large overall sample size, the limited numbers of deaths in some of the subgroup-specific analyses went along with rather wide confidence intervals. Our data do also not allow disentangling and quantifying the various factors other than earlier stage at diagnosis that might have contributed to the more favorable prognosis of screen-detected cancers. Although we controlled for multiple possible confounders, residual confounding by less than perfectly measured confounders or factors not controlled for cannot be ruled out.

Despite these limitations, our results have important practical implications. Physicians and patients should be aware of the very favorable prognosis after a screen-detected CRC and take this important prognostic factor into account in their treatment decisions. Communication of the favorable prognosis even in the rare case of CRC detection at screening, along with balanced communication of the protective effects \[[@R1]--[@R11]\] and the (albeit rare) potential harms of CRC screening, such as bleedings after polypectomy or overdiagnoses \[[@R13], [@R27]\], might help to enhance acceptance of and adherence to this powerful preventive measure.
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